New hope for rare cancers: drug combo shows promise in early trial
NCT ID NCT06041503
First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times
Summary
This phase 2 trial is testing a combination of two drugs, enfortumab vedotin and pembrolizumab, in people with rare cancers of the bladder, urinary tract, or testicles. The study aims to see if these drugs can shrink tumors or slow disease progression. About 68 adults will receive the drugs intravenously over several cycles, with treatment continuing for up to 5 years if it helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- enfortumab vedotin and pembrolizumab
- What this could lead to
- If successful, this could provide a new treatment option for people with rare genitourinary cancers that are hard to treat.
- What could go wrong
- This is an early-phase trial with only 68 participants, so results may not apply to everyone. The drugs can cause side effects like nerve damage, skin reactions, and immune-related issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE BLADDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.